pharma · Focal Segmental Glomerulosclerosis · Immunoglobulin A Nephropathy (IgAN) · TVTX
Travere Therapeutics
Travere Therapeutics is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker TVTX. Primary therapeutic focus areas include Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy
Company details
- Status
- Public
- HQ
- 3611 Valley Centre Dr, Suite 300, San Diego, California 92130, US
- Founded
- 2020
- Employees
- 506
- Programs
- 13
- Drugs
- 9
- Patents
- 1
RTRX-RE021-201
Phase 2 · small molecule · Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Alport syndrome (AS)
RTRX-RE021-201 for Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Alport syndrome (AS) is a Phase 2 program (small_molecule) at Travere Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code RTRX-RE021-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Travere Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Alport syndrome (AS)
- Status
- active
- Trials
- 1